Of these, 11 patients were excluded before the pre-assay questionnaire due to ineligible staging (n = 9), main tumor location in the rectum (n = 1), and double cancer (n = 1); 19 patients were excluded due to start of adjuvant chemotherapy before availability of the 12-RS results (n = 8); tumor sampling failure (n = 3); inappropriateness to continue the study (n = 1), patient withdrawal (n = 1); and deficient MMR known before post-assay assessment (n = 6). The gene discussed is MRC1; the disease is neoplasm.